rs515726204
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_031448.6(C19orf12):βc.171_181delβ(p.Gly58ArgfsTer10) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000812 in 1,614,004 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ).
Frequency
Genomes: π 0.000085 ( 0 hom., cov: 32)
Exomes π: 0.000081 ( 0 hom. )
Consequence
C19orf12
NM_031448.6 frameshift
NM_031448.6 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 7.26
Genes affected
C19orf12 (HGNC:25443): (chromosome 19 open reading frame 12) This gene encodes a small transmembrane protein. Mutations in this gene are a cause of neurodegeneration with brain iron accumulation-4 (NBIA4), but the specific function of the encoded protein is unknown. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Dec 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. There are 13 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 19-29702956-AACAGCCCCCCG-A is Pathogenic according to our data. Variant chr19-29702956-AACAGCCCCCCG-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 31155.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
C19orf12 | NM_031448.6 | c.171_181del | p.Gly58ArgfsTer10 | frameshift_variant | 3/3 | ENST00000323670.14 | NP_113636.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
C19orf12 | ENST00000323670.14 | c.171_181del | p.Gly58ArgfsTer10 | frameshift_variant | 3/3 | 2 | NM_031448.6 | ENSP00000313332 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000855 AC: 13AN: 152134Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
13
AN:
152134
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000762 AC: 19AN: 249194Hom.: 0 AF XY: 0.0000890 AC XY: 12AN XY: 134876
GnomAD3 exomes
AF:
AC:
19
AN:
249194
Hom.:
AF XY:
AC XY:
12
AN XY:
134876
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000807 AC: 118AN: 1461870Hom.: 0 AF XY: 0.0000798 AC XY: 58AN XY: 727240
GnomAD4 exome
AF:
AC:
118
AN:
1461870
Hom.:
AF XY:
AC XY:
58
AN XY:
727240
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000855 AC: 13AN: 152134Hom.: 0 Cov.: 32 AF XY: 0.0000673 AC XY: 5AN XY: 74324
GnomAD4 genome
AF:
AC:
13
AN:
152134
Hom.:
Cov.:
32
AF XY:
AC XY:
5
AN XY:
74324
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:8Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 30, 2021 | Frameshift variant predicted to result in protein truncation, as the last 84 amino acids are replaced with 9 different amino acids; This variant is associated with the following publications: (PMID: 23269600, 28347614, 23494994, 24636776, 23436634, 21981780) - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Jul 13, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Dec 01, 2022 | - - |
Hereditary spastic paraplegia 43 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | This sequence change creates a premature translational stop signal (p.Gly69Argfs*10) in the C19orf12 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 84 amino acid(s) of the C19orf12 protein. This variant is present in population databases (rs515726204, gnomAD 0.02%). This premature translational stop signal has been observed in individuals with autosomal recessive neurodegeneration with brain iron accumulation or mitochondria protein-associated neurodegeneration (PMID: 21981780, 23436634, 28641177, 30392167). It is commonly reported in individuals of Polish ancestry (PMID: 21981780, 23436634, 28641177, 30392167). ClinVar contains an entry for this variant (Variation ID: 31155). For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | 3billion | Jan 03, 2022 | Frameshift: predicted to result in a loss or disruption of normal protein function through protein truncation. Multiple pathogenic variants are reported in the predicted truncated region (PVS1_S). The variant has been reported to be associated with C19orf12 related disorder (ClinVar ID: VCV000031155, PMID:21981780).It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000100, PM2_M). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline. - |
Neurodegeneration with brain iron accumulation 4 Pathogenic:1Other:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 15, 2013 | - - |
not provided, no classification provided | literature only | GeneReviews | - | Founder variant in Eastern European (Polish) population; Associated with juvenile onset - |
C19orf12-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 23, 2024 | The C19orf12 c.204_214del11 variant is predicted to result in a frameshift and premature protein termination (p.Gly69Argfs*10). This variant has primarily been reported in the homozygous or compound heterozygous states in individuals with autosomal recessive neurodegeneration with brain iron accumulation (see for example, Table 1, Hartig et al. 2011. PubMed ID: 21981780; Table 1, Schulte et al. 2012. PubMed ID: 23436634; Goldman et al. 2013. PubMed ID: 23494994). In these studies heterozygous carriers were reported as unaffected. However, in a single case it has also been associated with autosomal dominant neurodegeneration with brain iron accumulation (Table 1, Sparber et al. 2021. PubMed ID: 33607528). This variant has been classified as pathogenic in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/31155/). Given the evidence, we interpret this variant as pathogenic in the context of autosomal recessive disease, and as a variant of uncertain significance in the context of autosomal dominant disease. - |
Neurodegeneration with brain iron accumulation Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 29, 2023 | Variant summary: C19orf12 c.171_181del11/p.Gly58ArgfsX10 (legacy name c.204_214del11/p.Gly69ArgfsX10) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been associated with Neurodegeneration With Brain Iron Accumulation in HGMD. The variant allele was found at a frequency of 7.6e-05 in 249194 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in C19orf12 causing Neurodegeneration With Brain Iron Accumulation (7.6e-05 vs 0.0006). c.171_181del11 has been reported in the literature in multiple individuals affected with Neurodegeneration With Brain Iron Accumulation (Gregory_2019, Sparber_2021, etc). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five ClinVar submitters have submitted clinical-significance assessments for this variant to ClinVar after 2014. All laboratories classified the variant as pathogenic (n=3) or likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at